Arkolith/Insider Trading/VINC/Form 4

Izumi Raquel E.

See Remarks, DirectorVincerx Pharma, Inc. (VINC) · full profile →Form 4 · filed Aug 14, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
12
0 non-derivative · 12 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Aug 12, 2024Disposed to issuer(D)124K——0
Aug 12, 2024Grant(A)124K——124K
Aug 12, 2024Disposed to issuer(D)41K——0
Aug 12, 2024Grant(A)41K——165K
Aug 12, 2024Disposed to issuer(D)77K——0
Aug 12, 2024Grant(A)90K——90K
Aug 12, 2024Disposed to issuer(D)60K——0
Aug 12, 2024Grant(A)60K——60K
Aug 12, 2024Disposed to issuer(D)60K——0
Aug 12, 2024Grant(A)60K——60K
Aug 12, 2024Disposed to issuer(D)90K——0
Aug 12, 2024Grant(A)77K——77K

Transaction Codes

D
Disposition to the issuer
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-24-097322) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML